Interleukin-2: The Immune Growth Factor That Fights Cancer
IL-2 is a 133-amino-acid immune growth factor that can dramatically boost cancer-killing immune cells, but early clinical trials showed severe side effects at high doses.
Quick Facts
What This Study Found
IL-2 is a 133-amino acid protein (molecular weight 15,420 daltons) produced by activated T-cells. Its gene sits on chromosome 4. The IL-2 receptor is a 272-amino acid protein (55,000 daltons).
IL-2 does not just make immune cells copy themselves. It moves cells from a resting state (G1) through to DNA synthesis (S phase). During this process, the proto-oncogene c-myb increases 6 to 7 times above normal levels.
The most exciting clinical development: IL-2 could expand LAK cells (lymphokine-activated killer cells) and TIL (tumor-infiltrating lymphocytes) that attack cancer. Early human trials showed both therapeutic promise and significant toxicity.
Thymosin fraction 5 and thymosin alpha 1 could modulate IL-2 receptor expression on human blood cells, potentially increasing the effectiveness of IL-2 therapy.
Key Numbers
How They Did This
Narrative review covering IL-2 research from 1984 to September 1986. Covered molecular biology, mechanism of action, cell biology, disease associations, animal models, early clinical trials, and interaction with thymosin peptides.
Why This Research Matters
This review captured a pivotal moment in cancer immunotherapy. IL-2 was about to become the first immunotherapy approved for cancer (FDA approved in 1992 for kidney cancer). The connection to thymosin alpha 1 as an IL-2 receptor enhancer suggested combination approaches that are still studied today.
The Bigger Picture
IL-2 became one of the first approved cancer immunotherapies. Understanding its biology paved the way for modern checkpoint inhibitors and adoptive cell therapy.
What This Study Doesn't Tell Us
As a 1987 review, much of the clinical data was preliminary. The toxicity of IL-2 therapy proved to be a major limitation in practice. The thymosin-IL-2 combination was promising but not yet clinically tested.
Questions This Raises
- ?Can thymosin alpha 1 reduce IL-2 side effects while maintaining efficacy?
- ?What is the optimal IL-2 dosing schedule for cancer?
Trust & Context
- Key Stat:
- 133 amino acids The complete IL-2 protein — one of the most potent immune activators known
- Evidence Grade:
- Moderate — comprehensive review of molecular biology and early-phase clinical data.
- Study Age:
- Published in 1987 — IL-2 has since been FDA-approved for certain cancers, validating the early research reviewed here.
- Original Title:
- Recent advances in the understanding of the biochemistry and clinical pharmacology of interleukin-2.
- Published In:
- Lymphokine research, 6(1), 45-57 (1987)
- Authors:
- Fletcher, M, Goldstein, A L(11)
- Database ID:
- RPEP-00043
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What is IL-2?
Interleukin-2 is a protein made by activated T-cells that signals other immune cells to multiply and attack. It is one of the most potent natural immune activators and is used as a cancer drug.
Why is IL-2 combined with other treatments?
IL-2 alone causes dangerous side effects at effective doses. Combinations with thymosin alpha 1 or other agents may allow lower doses while maintaining cancer-fighting activity.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00043APA
Fletcher, M; Goldstein, A L. (1987). Recent advances in the understanding of the biochemistry and clinical pharmacology of interleukin-2.. Lymphokine research, 6(1), 45-57.
MLA
Fletcher, M, et al. "Recent advances in the understanding of the biochemistry and clinical pharmacology of interleukin-2.." Lymphokine research, 1987.
RethinkPeptides
RethinkPeptides Research Database. "Recent advances in the understanding of the biochemistry and..." RPEP-00043. Retrieved from https://rethinkpeptides.com/research/fletcher-1987-recent-advances-in-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.